ABL Bio Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.ablbio.com

Country

South Korea

Exchange

KOSDAQ

ABL Bio Inc., a biotech research company develops therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease.

Its portfolio also includes ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor, and ABL102 for the treatment of solid and blood tumor ABL103 for the treatment solid cancers.

Its portfolio also includes ABL104 for the treatment of solid tumor, and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Key Stats

52-Week Range

₩63700.00₩257500.00

Beta0.23

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean Price₩257500.00

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.